ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Skin Diseases
Food Hypersensitivity
Hypersensitivity
Pruritus
Psoriasis

Eczema trials near Hanyang, Seoul, KOR:

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (ADHAND)

The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...

Enrolling
Atopic Hand Eczema
Atopic Dermatitis
Drug: Placebo
Drug: Tralokinumab

Phase 3

LEO Pharma
LEO Pharma

Seoul, Korea, Republic of and 75 other locations

The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have...

Active, not recruiting
Dermatitis, Atopic
Drug: GSK1070806

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 58 other locations

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK10...

Active, not recruiting
Dermatitis, Atopic
Drug: GSK1070806
Drug: Placebo

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 92 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Seoul, Korea, Republic of and 536 other locations

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluat...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: Lutikizumab

Phase 2

AbbVie
AbbVie

Bucheon-si, Gyeonggido, Korea, Republic of and 22 other locations

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants w...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of and 45 other locations

assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult pa...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A

Phase 3

AbbVie
AbbVie

Seoul, Seoul Teugbyeolsi, Korea, Republic of and 93 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

Phase 3

Amgen
Amgen

Seoul, Korea, Republic of and 536 other locations

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.

Active, not recruiting
Atopic Dermatitis
Combination Product: Rocatinlimab AI
Combination Product: Rocatinlimab Prefilled Syringe

Phase 3

Amgen
Amgen

Seoul, Korea, Republic of and 46 other locations

A Multicenter, Randomized, Single-Blind, Phase Ⅱ Clinical Trial and Open Label Long-term Observation Study of ADSTEM Inj. to Evaluate the Safety and...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Biological: ADSTEM Inj.

Phase 2

EHL Bio

Seoul, Seoulteukbyeolsi, Korea, Republic of and 5 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems